DUBLIN–(BUSINESS WIRE)–Research and Markets has actually announced the addition of the “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2016” report to their offering.
This report supplies comprehensive article regard the therapeutic progress when it come to Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), finish along with comparative analysis at numerous stages, therapeutics assessment by drug target, mechanism of action (MoA), course of administration (RoA) and molecule type, along along with the most recent updates, and featured news and press releases. It additionally reviews crucial users associated with the therapeutic progress when it come to Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and distinct features regard late-phase and discontinued projects.
The report improves decision-making capabilities and aids to make efficient counter-strategies to obtain competitive advantage. It strengthens R&D pipelines by determining brand-new targets and MoAs to create first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
- Therapeutics Development
- Pipeline product and services when it come to Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Overview
- Pipeline product and services when it come to Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Comparative Analysis
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Therapeutics under progress by Companies
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Therapeutics under Investigation by Universities/Institutes
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) product and services Glance
- Late-phase Products
- Clinical-phase Products
- Early-phase Products
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – product and services under progress by Companies
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – product and services under Investigation by Universities/Institutes
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Organizations associated with Therapeutics Development
- Altor BioScience Corporation
- Aprea AB
- arGEN-X BV
- Ariad Pharmaceuticals, Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals, Inc.
- Baxalta Incorporated
- BioSight Ltd.
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Deciphera Pharmaceuticals, LLC
- Eisai Co., Ltd.
- EpiZyme, Inc.
- F. Hoffmann-La Roche Ltd.
- Galena Biopharma, Inc.
- Gamida Cell Ltd.
- GlycoMimetics, Inc.
- HEC Pharm Co., Ltd.
- Hybrigenics S.A.
- Ilyang Pharmaceutical Co., Ltd.
- Incyte Corporation
- Lixte Biotechnology Holdings, Inc.
- Mirna Therapeutics, Inc.
- Natco Pharma Limited
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- Oribase Pharma
- Panther Biotechnology, Inc.
- Pfizer Inc.
- Sanofi
- Sun Pharma Advanced Study Business Ltd.
- Takeda Pharmaceutical Business Limited
- Targazyme, Inc.
- Teva Pharmaceutical Industries Ltd.
For much more article browse through http://ift.tt/28POIXN.
